CymaBay Therapeutics, Inc.
CBAY · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.02 | -0.00 | 3.54 | 0.50 |
| FCF Yield | -1.03% | -1.66% | -2.28% | 0.73% |
| EV / EBITDA | -60.90 | -43.68 | 294.13 | -36.83 |
| Quality | ||||
| ROIC | -10.42% | -7.42% | -0.05% | -16.43% |
| Gross Margin | 1.75% | 0.00% | 99.32% | 0.00% |
| Cash Conversion Ratio | 0.65 | 0.77 | 31.48 | -0.22 |
| Growth | ||||
| Revenue 3-Year CAGR | 3,143,744.53% | 3,141,821.01% | 3,141,821.01% | -100.00% |
| Free Cash Flow Growth | -5.41% | -2.50% | -509.03% | 133.22% |
| Safety | ||||
| Net Debt / EBITDA | 2.17 | 5.26 | 15.95 | -1.49 |
| Interest Coverage | -8.36 | -6.65 | -0.02 | -6.10 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -6,152.14 | -1,143.21 | -1,957.39 | -738.54 |